BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Review of Hematology 2017;11:57-70. [DOI: 10.1080/17474086.2018.1407645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Link H, Kerkmann M, Holtmann L; for the Working Groups Supportive Care (AGSMO), Medical Oncology (AIO) of the German Cancer Society (DKG). Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections. Support Care Cancer. [DOI: 10.1007/s00520-022-06920-y] [Reference Citation Analysis]
2 Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165-73. [PMID: 33861303 DOI: 10.1182/blood.2021011568] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 77.0] [Reference Citation Analysis]
3 Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanasis-Stathopoulos I, Sklirou AD, Malandrakis P, Eleutherakis-Papaiakovou E, Migkou M, Trougakos IP, Dimopoulos MA. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med 2021. [PMID: 34283338 DOI: 10.1007/s10238-021-00746-4] [Reference Citation Analysis]
4 Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R, Rapoport B. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 2021;29:1129-38. [PMID: 33230644 DOI: 10.1007/s00520-020-05906-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia 2021. [PMID: 34725454 DOI: 10.1038/s41375-021-01450-8] [Reference Citation Analysis]
6 Chatzikonstantinou T, Herishanu Y, Montserrat E, Ghia P, Cuneo A, Foà R, Scarfò L. COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now. Cancer J 2021;27:328-33. [PMID: 34398560 DOI: 10.1097/PPO.0000000000000535] [Reference Citation Analysis]
7 Fried LJ, Criscito MC, Stevenson ML, Pomeranz MK. Chronic lymphocytic leukemia and the skin: implications for the dermatologist. Int J Dermatol 2021. [PMID: 33951189 DOI: 10.1111/ijd.15629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Trougakos IP, Dimopoulos MA. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Adv 2021;5:4398-405. [PMID: 34529762 DOI: 10.1182/bloodadvances.2021005444] [Reference Citation Analysis]
9 Steingrímsson V, Gíslason GK, Þorsteinsdóttir S, Rögnvaldsson S, Gottfreðsson M, Aspelund T, Turesson I, Björkholm M, Landgren O, Kristinsson SY. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. Eur J Haematol 2021;106:346-53. [PMID: 33211356 DOI: 10.1111/ejh.13553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Steingrímsson V, Gíslason GK, Aspelund T, Turesson I, Björkholm M, Landgren O, Kristinsson SY. A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival. Eur J Haematol 2020;105:547-54. [PMID: 32575150 DOI: 10.1111/ejh.13477] [Reference Citation Analysis]
11 Cho HJ, Baek DW, Kim J, Lee JM, Moon JH, Sohn SK. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Rev Hematol 2021;:1-12. [PMID: 34375536 DOI: 10.1080/17474086.2021.1967139] [Reference Citation Analysis]
12 Sakhdari A, Tang G, Ginsberg LE, Hirsch-Ginsberg CF, Bueso-Ramos CE, Medeiros LJ, Miranda RN. Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy. Case Rep Pathol 2019;2019:4915086. [PMID: 30941227 DOI: 10.1155/2019/4915086] [Reference Citation Analysis]
13 Vigón L, Sánchez-Tornero A, Rodríguez-Mora S, García-Pérez J, Corona de Lapuerta M, Pérez-Lamas L, Casado-Fernández G, Moreno G, Torres M, Mateos E, Murciano-Antón MA, Alcamí J, Pérez-Olmeda M, López-Jiménez J, García-Gutiérrez V, Coiras M, On Behalf Of Multidisciplinary Group Of Study Of Covid-Mgs-Covid. Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection. J Clin Med 2022;11:2137. [PMID: 35456230 DOI: 10.3390/jcm11082137] [Reference Citation Analysis]
14 Eichhorst B, Hallek M, Goede V. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med 2018;58:7-13. [PMID: 30527922 DOI: 10.1016/j.ejim.2018.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bhat SA, Woyach JA. Boosting BNT162b2 vaccine efficacy in CLL. Blood 2022;139:639-40. [PMID: 35113151 DOI: 10.1182/blood.2021014903] [Reference Citation Analysis]
16 Chen KY, Brunk KM, Patel BA, Stocker KJ, Auten JJ, Buhlinger KM, Muluneh B. Pharmacists' Role in Managing Patients with Chronic Lymphocytic Leukemia. Pharmacy (Basel) 2020;8:E52. [PMID: 32230834 DOI: 10.3390/pharmacy8020052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Puła B, Pruszczyk K, Pietrusza E, Morawska M, Piszczek W, Kalicińska E, Szeremet A, Tryc-szponder J, Wąsik-szczepanek E, Drozd-sokołowska J, Krzemień H, Rejus A, Gajewska M, Wiśniewski K, Wysocki M, Majeranowski A, Paszkiewicz-kozik E, Steckiewicz P, Szukalski Ł, Bołkun Ł, Długosz-danecka M, Giannopoulos K, Jamroziak K, Lech-marańda E, Hus I. Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. Cancers 2022;14:558. [DOI: 10.3390/cancers14030558] [Reference Citation Analysis]
18 Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, Bystry DM, Phelps MA, Andritsos LA, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT. Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clin Cancer Res 2020;26:6187-95. [PMID: 32958702 DOI: 10.1158/1078-0432.CCR-20-1280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Arzoun H, Srinivasan M, Sandoval S, Lee B. A Systematic Review on the Prevention and Control of Opportunistic Infections in Patients With Chronic Lymphocytic Leukemia Complicated by Richter’s Transformation. Cureus. [DOI: 10.7759/cureus.22927] [Reference Citation Analysis]
20 Laws HJ, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, Heininger U, Hilgendorf I, Kern W, Kling K, Kobbe G, Külper W, Lehrnbecher T, Meisel R, Simon A, Ullmann A, de Wit M, Zepp F. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:588-644. [PMID: 32350583 DOI: 10.1007/s00103-020-03123-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
21 Palomino GJQ, Sá NAR, Guerreiro DD, Gomes FDR, da Silva RF, Lopes EPF, Paes VM, Gataí PHS, Alves BG, Pessoa ODL, Figueiredo JR, Rocha RMP, Rodrigues APR. Induced-damages on preantral follicles by withanolide D, a potent chemotherapy candidate are not attenuated by melatonin. Reprod Toxicol 2021;104:125-33. [PMID: 34274432 DOI: 10.1016/j.reprotox.2021.07.005] [Reference Citation Analysis]
22 Saburi M, Ogata M, Itani K, Kohno K, Soga Y, Kondo Y, Kawano Y, Nakayama T. Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma. J Clin Exp Hematop 2018;58:175-9. [PMID: 30305474 DOI: 10.3960/jslrt.18019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E, Angelopoulou M, Baltadakis I, Panayiotidis P, Trougakos IP, Vassilakopoulos TP, Pagoni M, Dimopoulos MA. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers (Basel) 2021;13:4480. [PMID: 34503290 DOI: 10.3390/cancers13174480] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Takizawa J, Izutsu K, Nagai H, Fukase K, Nakamura M, Jinushi M, Suzumiya J. Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR). J Clin Exp Hematop 2021;61:126-34. [PMID: 34092721 DOI: 10.3960/jslrt.20044] [Reference Citation Analysis]
25 Hus I, Salomon-Perzyński A, Tomasiewicz K, Robak T. The management of hematologic malignancies during the COVID-19 pandemic. Expert Opin Pharmacother 2021;22:565-82. [PMID: 33342308 DOI: 10.1080/14656566.2020.1849143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]